Beyond Air

Aging Populations And Precision Medicine Will Reshape Respiratory Care

AnalystHighTarget

Not Invested

Consensus Narrative from 5 Analysts

Published

16 Aug 25

Updated

21 Aug 25

AnalystHighTarget's Fair Value

US$14.00

84.7% undervalued

21 Aug

US$2.14

-76.9%

-12.7%

Author's Valuation

US$14.0

84.7% undervalued

AnalystHighTarget Fair Value

Narrative

Updates0

AnalystHighTarget Fair Value

US$14.0

84.7% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

39.08%

Medical Equipment revenue growth rate

0.44%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

9.68%

Calculation

US$5.00m

Earnings '28

42.28x

PE Ratio '28

US$211.55m

Market Cap '28

US$211.55m

Market Cap '28

11.48m

No. shares '28

US$18.42

Share Price '28

US$18.42 Share Price '28

Discounted to 2025 @ 9.59% p.a.

US$14.00

Fair Value '25